Feasibility of indirect treatment comparisons for approved therapies in epidermolysis bullosa (ESDR 2026) - Oct 5, 2026 - Abstract #394; "A search identified studies in junctional/dystrophic EB treated with Oleogel-S10 (also known as birch bark extract/birch triterpenes), beremagene geperpavec-svdt (B-VEC) or prademagene zamikeracel (pz-cel), without limits on language, geography or design...Any ITC would have major limitations. EB therapies are complementary and address distinct aspects of EB management."
Infectious Disease
|
|
Jemima Mellerio 1; Emily Gorell 2; Rafaël Minacori 3; Leo Lin 4; Mawuena Binka 4; Tanja Plate 5; Hannah Kilvert 6; Sarah Smith 6; Jyoti Garg 6; Lydia Francis 7
|